Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

Clinical Epigenetics

Table 2 Romidepsin trials reported in 2009 and 2010

Combination therapy	Type of cancer	Phase	N	Outcome (most relevant findings)	Literature
None	Cutaneous T-cell lymphoma	II	71	Response rate 34% 4CR, 20PR	Piekarz et al. (2009a, b)
None	Cutaneous T-cell lymphoma	II	27	2CCR, 13PR	Kim et al. (2009)^a
None	Relapsed peripheral T-cell lymphoma	II	46	5CR, 10PR	Piekarz et al. (2009a, b)^a
None	Metastatic castration-resistant prostate cancer	II	35	2PR	Molife et al. (2010)
None	Advanced colorectal cancer	II	25	4SD; No objective response	Whitehead et al. (2009)
Bortezomib	Refractory multiple myeloma	II	5	2 Minimal responses	Berenson et al. (2009a, b)^a

ISSN: 1868-7083